無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ペスト : パイプライン分析

Plague - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 245959
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.75円で換算しております。
Back to Top
ペスト : パイプライン分析 Plague - Pipeline Review, H1 2019
出版日: 2019年02月01日 ページ情報: 英文 64 Pages
概要

ペストはペスト菌という細菌により引き起こされる感染症です。この細菌は主に、ネズミやそれに寄生するノミから発見されます。人間や他の動物は、ネズミとの接触やノミに噛まれることによりペストに感染します。かつてはペストは文明全体を崩壊させたこともありました。現在では生活水準の改善や抗生物質の進化により、ペストは一般的疾患ではなくなっています。ペストの一般的症状として、鼠頚部や腋下、頚部などに横痃(リンパ節が腫れ上がり、痛く感じる場所)が出現します。ペストの中でも特に稀で深刻な症状の場合は、肺が侵され、ヒトからヒトへと感染していきます。

当レポートでは、世界各国でのペスト治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

ペストの概要

治療薬の開発

  • ペスト向けパイプライン製品:概要
  • ペスト向けパイプライン製品:比較分析

各企業で開発中のペスト治療薬

大学/研究機関で研究中のペスト治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

ペスト治療薬:開発中の製品の一覧(企業別)

ペスト治療薬:研究中の製品の一覧(大学/研究機関別)

ペスト治療薬の開発に従事している企業

  • Aradigm Corporation
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.

ペスト:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • 炭疽菌・ペスト菌ワクチン
  • ARD-3100
  • 塩酸シプロフロキサシン
  • ペスト菌ワクチン
  • 肺血小板ワクチン
  • ペスト向けタンパク質チロシンホスファターゼ (YopH) 阻害剤
  • TP-271
  • ペスト菌ワクチン

ペスト治療薬:最新の薬剤プロファイル

ペスト治療薬:開発が休止状態の製品

ペスト治療薬:開発が中止された製品

ペスト関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Plague - Pipeline by Achaogen Inc, H1 2019
  • Plague - Pipeline by Aradigm Corp, H1 2019
  • Plague - Pipeline by Greffex Inc, H1 2019
  • Plague - Pipeline by iBio Inc, H1 2019
  • Plague - Pipeline by Prokarium Ltd, H1 2019
  • Plague - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Plague - Dormant Projects, H1 2019
  • Plague - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11076IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2019, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plague - Overview
  • Plague - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Plague - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plague - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Aradigm Corp
    • Greffex Inc
    • iBio Inc
    • Prokarium Ltd
    • Tetraphase Pharmaceuticals Inc
  • Plague - Drug Profiles
    • (anthrax + plague) (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anthrax + plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GreAnPla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GrePla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISAS-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumonic plaque vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VypVaxDuo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2017: DynPorts clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation
      • Feb 14, 2013: BioDiem Extends Cooperative Agreement with USAMRIID
      • Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development
      • Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial
      • May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
      • Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top